Copyright © . Transposon Therapeutics, Inc. All rights reserved. Privacy Policy Terms of Use
✕
✕
‹ Pipeline › TPN-101
✕
Progressive Supranuclear Palsy (PSP)
About PSP
A devastating orphan disease, with mean survival of 6 to 7 years, characterized by early postural instability and falls, vertical gaze palsy, akinesia, rigidity, pseudobulbar palsy and frontal dysfunction with cognitive and behavioral changes.
✕
Progressive Supranuclear Palsy (PSP)
Why TPN-101?
PSP is a primary 4R tauopathy, that is, a disease associated with abnormal accumulation of neurotoxic tau proteins. In the PSP brain, LINE-1 expression is increased and correlates with tau neurofibrillary tangles and interferon-related gene expression.
Key Findings from TPN-101 Phase 2a Study in PSP:
- Reductions in biomarkers (NfL and IL-6) signal potential therapeutic effects on neuroinflammation and neurodegeneration
- Clinical improvement emerges with prolonged treatment
- All doses of TPN-101 were well-tolerated
- Phase 3 clinical trial in planning